GE HealthCare (Nasdaq: GEHC) announces the U.S. FDA 510(k) Clearance of IONIC Health’s revolutionary nCommand Lite technology, aimed at mitig...
“The acquisition of CymaBay brings us a potential best-in-disease therapy that could transform the treatment landscape for people wit...
Isansys Lifecare, led by the visionary Keith Errey, has gained recognition in the global healthcare technology market, particularly through its suc...
“We are thrilled with the positive CHMP opinion, which reflects the significant cardiovascular risk reduction benefit that the bemped...
QIAGEN has announced a collaborative effort with the International Panel Physicians Association (IPPA) to bolster awareness of tuberculosis (TB) screening ...
Optinose, a pharmaceutical company specializing in treatments for ear, nose, and throat (ENT) and allergy conditions, has achieved a significant milestone ...
Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the Europea...
In 2023, Beckman Coulter and Fujirebio entered into a collaboration agreement focused on new biomarkers aligned with recently approved monoclonal a...
The new registry will prospectively collect detailed patient-level data enabling assessment of the natural history of the disease and treatment patterns, a...
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis Late-breaking dat...
Rob Truckenmiller, Senior Vice President, Head of US Vaccines, GSK, emphasized the importance of collaborative efforts and fi...
The Change Healthcare Ransomware Payment Change Healthcare, a key player in the medical services sector owned by UnitedHealth Group, fell victim t...
Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announ...
GMP material to be used in Phase Ib study in platinum-resistant ovarian cancer (PROC) patients scheduled to start this year. Previously reported Phase I sa...
© 2025 Biopharma Boardroom. All Rights Reserved.
